A dose‐ranging study of the effects of mequitazine on actual driving, memory and psychomotor performance as compared to dexchlorpheniramine, cetirizine and placebo

  title={A dose‐ranging study of the effects of mequitazine on actual driving, memory and psychomotor performance as compared to dexchlorpheniramine, cetirizine and placebo},
  author={Eef L Theunissen and Annemiek Vermeeren and Anita C M Van Oers and I van Maris and Johannes G Ramaekers},
  journal={Clinical \& Experimental Allergy},
Background Mequitazine is a so‐called ‘non‐sedative’ second‐generation antihistamine even though it has never been firmly established that this drug's sedative potential actually differs from that of the ‘sedative’ first‐generation antihistamines. 
Lack of effects between rupatadine 10 mg and placebo on actual driving performance of healthy volunteers
Rupatadine fumarate is a potent, selective, histamine H1‐receptor antagonist and PAF inhibitor with demonstrated efficacy for the relief of allergic rhinitis and should show no impairment on car driving.
A simulated car‐driving study on the effects of acute administration of levocetirizine, fexofenadine, and diphenhydramine in healthy Japanese volunteers
Antihistamines are often used for treating allergic rhinitis. However, many older antihistamines cause sedative side effects. The sedative effects of antihistamines on car‐driving have been
Sedation and antihistamines: an update. Review of inter‐drug differences using proportional impairment ratios
An extensive review of the literature collated the results of studies of H1 receptor antagonists to determine the extent to which a particular AH produced impairments on a battery of psychometric tests by calculating a proportional impairment ratio for each AH.
Repeated-dose effects of mequitazine, cetirizine and dexchlorpheniramine on driving and psychomotor performance.
Single doses of mequitazine 10 mg and dexchlorpheniramine Repetab 6 mg cause mild driving impairment, however, when taken over several days, the impairing effect wears off, possibly as a result of tolerance.
Effects of low‐dose mirtazapine on driving performance in healthy volunteers
This study aimed to assess whether a lower initial dose of mirtazapine can lessen the harmful effect on driving performance or not in a double‐blinded, placebo‐controlled crossover trial.
Short-Term Effects of Morning Versus Evening Dose of Hydroxyzine 50 mg on Cognition in Healthy Volunteers
It is concluded that hydroxyzine-induced impairment at tmax is more prominent after morning doses compared with evening doses and that the present study could not present direct evidence to substantiate the hypothesis that histamine availability inversely affects the magnitude of antihistamine impairment.
Effects of levocetirizine and diphenhydramine on regional glucose metabolic changes and hemodynamic responses in the human prefrontal cortex during cognitive tasks
This was the first study to measure regional cerebral glucose (energy) consumption and hemodynamic responses in young adults during cognitive tests after antihistamine administration.
A Randomized Trial on the Acute and Steady‐State Effects of a New Antidepressant, Vortioxetine (Lu AA21004), on Actual Driving and Cognition
Vortioxetine did not impair driving, cognitive, or psychomotor performance after single or multiple doses, and most of these effects disappeared after multiple doses of mirtazapine.
Acute and subchronic effects of bilastine (20 and 40 mg) and hydroxyzine (50 mg) on actual driving performance in healthy volunteers
It is concluded that hydroxyzine produces severe driving impairment after single doses and that this impairment only partly mitigates over time due to a lack of complete tolerance.


Does cetirizine belong to the new generation of antihistamines? An investigation into its acute and subchronic effects on highway driving, psychometric test performance and daytime sleepiness
Twenty‐seven healthy male volunteers participated in a double‐blind, five‐way crossover designed comparison of the new, selective H1‐receptor antagonist cetirizine and terfenadine versus the older H1-receptor antagonists triprolidine and placebo.
Quantitative effects of cetirizine and diphenhydramine on mental performance measured using an automobile driving simulator.
Data indicate that these doses of cetirizine produce little or no effect on cognitive function or mental performance, and diphenhydramine produced impaired mental performance and drowsiness.
Sedation and antihistamines: a review of inter‐drug differences using proportional impairment ratios
A complete evaluation of sedation should be performed through standardised objective and subjective tests, shown to be sensitive to the central effects of AHs.
A placebo-controlled assessment of mequitazine and astemizole in tests of psychomotor ability.
None of the treatments produced any significant or consistent effects when assessed on objective and subjective measures of performance, critical flicker fusion threshold, sedation and sleep and there were no treatment differences in the nature and number of adverse effects reported.
The Acute and Sub-chronic Effects of Levocetirizine, Cetirizine, Loratadine, Promethazine and Placebo on Cognitive Function, Psychomotor Performance, and Weal and Flare
In a study where the psychometric assessments were shown to be sensitive to impairment, l-CTZ 5 mg was found not only to be a potent inhibitor of the histamine-induced weal and flare reaction, but also to show evidence of potent peripheral inhibition of histamine.
Effects of mefloquine alone and with alcohol on psychomotor and driving performance
Mefloquine did not impair driving performance but rather improved it in the longer test, suggesting that the drug may possess psychostimulating properties.
Differentiating the effects of centrally acting drugs on arousal and memory: an event-related potential study of scopolamine, lorazepam and diphenhydramine
It is concluded that benzodiazepines and anticholinergic drugs both reduce arousal and induce amnesia, but these effects are not interdependent.
Acute and subchronic effects of the H1-histamine receptor antagonist ebastine in 10, 20 and 30 mg dose, and triprolidine 10 mg on car driving performance.
The results suggest that ebastine in doses up to 30 mg may be relatively safe for use by those who drive motor vehicles while under medication, and the results do not warrant such a conclusion for triprolidine 10 mg.
Antihistamine effects on actual driving performance in a standard test: a summary of Dutch experience, 1989‐94
The review summarizes the major results of eight double‐blind, placebo‐controlled, volunteer studies undertaken by three independent institutions for showing the effects on actual driving performance
The clinical safety of H1‐receptor antagonists: An EAACI position paper *
Since antihistamines are used to treat non-life-threatening disorders, their risk/benefit ratio must be carefully evaluated and the safety issue is of central importance because of the widespread use of antihistamine in current medical practice.